Advanced interstitial chemotherapy for treating malignant glioma

References

• Tanaka S, Louis DN, Curry WT, et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013;10:14–26.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123.
   PubMed Web of Science ®Google Scholar
• Stupp R, Gander M, Leyvraz S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2:552–560.
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1018.
   PubMed Web of Science ®Google Scholar
• Affronti ML, Heery CR, Herndon JE II, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115:3501–3511.
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of nanobiotechnology in the personalized management of glioblastoma multiforme. Nanomedicine (Lond). 2011;6:411–414.
   PubMed Web of Science ®Google Scholar
• Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62:564–576.
   PubMed Web of Science ®Google Scholar
• Stummer W, Novotny A, Stepp H, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93:1003–1013.
   PubMed Web of Science ®Google Scholar
• Aoki T, Hashimoto N, Matsutani M. Management of glioblastoma. Expert Opin Pharmacother. 2007;8:3133–3146.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262–1267.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178–7187.
   PubMed Web of Science ®Google Scholar
• Goellner EM, Grimme B, Brown AR, et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res. 2011;71:2308–2317.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother. 2010;10:1537–1544.
   PubMed Web of Science ®Google Scholar
• Wick W, Wick A, Weiler M, et al. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep. 2011;11:305–312.
   PubMed Web of Science ®Google Scholar
• Lopez KA, Tannenbaum AM, Assanah MC, et al. Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res. 2011;71:3963–3971.
   PubMed Web of Science ®Google Scholar
• Tseng YY, Liao JY, Chen WA, et al. Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies. Expert Opin Drug Deliv. 2013;10:879–888.
   PubMed Web of Science ®Google Scholar
• Loeffler JS, Alexander E III, Wen PY, et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst. 1990;82:1918–1921.
   PubMedGoogle Scholar
• Tomita T. Interstitial chemotherapy for brain tumors: review. J Neurooncol. 1991;10:57–74.
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55–57.
   PubMed Web of Science ®Google Scholar
• Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release. 2001;74:63–67.
   PubMed Web of Science ®Google Scholar
• Ewend MG, Sampath P, Williams JA, et al. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery. 1998;43:1185–1193.
   PubMed Web of Science ®Google Scholar
• Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw. 2005;3:721–728.
   PubMedGoogle Scholar
• Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg. 1992;76:640–647.
   PubMed Web of Science ®Google Scholar
• Bota DA, Desjardins A, Quinn JA, et al. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag. 2007;3:707–715.
   PubMedGoogle Scholar
• Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res. 1996;13:683–691.
   PubMed Web of Science ®Google Scholar
• Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41:403–419.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88.
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet. 1995;345:1008–1012.
   PubMed Web of Science ®Google Scholar
• Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294.
   Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997;41:44–48.
   PubMed Web of Science ®Google Scholar
• Lu CT, Zhao YZ, Wong HL, et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014;9:2241–2257.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. Tumori. 2008;94:271–277.
   PubMed Web of Science ®Google Scholar
• Koffie RM, Farrar CT, Saidi LJ, et al. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A. 2011;108:18837–18842.
   PubMed Web of Science ®Google Scholar
• Tosi G, Costantino L, Ruozi B, et al. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008;5:155–174.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3:90–105, 151.
   PubMedGoogle Scholar
• Jain KK. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother. 2007;7:363–372.
   PubMed Web of Science ®Google Scholar
• Lillehei KO, Kong Q, Withrow SJ, et al. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery. 1996;39:1191–1197.
   PubMed Web of Science ®Google Scholar
• Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg. 1988;68:1–17.
   PubMed Web of Science ®Google Scholar
• Rhines LD, Sampath P, Dolan ME, et al. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 2000;60:6307–6310.
   PubMed Web of Science ®Google Scholar
• Sheleg SV, Korotkevich EA, Zhavrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol. 2002;60:53–59.
   PubMed Web of Science ®Google Scholar
• Ebrahimi Shahmabadi H, Movahedi F, Koohi Moftakhari Esfahani M, et al. Efficacy of Cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma. Tumour Biol. 2014;35:4799–4806.
   PubMed Web of Science ®Google Scholar
• Raza SM, Pradilla G, Legnani FG, et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther. 2005;5:477–494.
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Stuart RM, Yun J, et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol. 2011;13:886–893.
   PubMed Web of Science ®Google Scholar
• Zhou J, Atsina KB, Himes BT, et al. Novel delivery strategies for glioblastoma. Cancer J. 2012;18:89–99.
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med. 2006;79:141–152.
   PubMedGoogle Scholar
• Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91:2076–2080.
   PubMed Web of Science ®Google Scholar
• Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg. 2000;92:599–605.
   PubMed Web of Science ®Google Scholar
• Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30:2302–2318.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Tseng YY, Wang YC, Su CH, et al. Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: in vitro and in vivo studies. Colloids Surf B. 2015;134:254–261.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Van Den Bent MJ, et al. Changing paradigms–an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165–180.
   PubMed Web of Science ®Google Scholar
• Kappelle AC, Postma TJ, Taphoorn MJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:118–120.
   PubMed Web of Science ®Google Scholar
• Xu X, Xie K, Zhang XQ, et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A. 2013;110:18638–18643.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Raghavan D. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Nat Clin Pract Oncol. 2008;5:444–454.
   PubMedGoogle Scholar
• Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292:470–484.
   PubMed Web of Science ®Google Scholar
• Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29:5171–5184.
   PubMed Web of Science ®Google Scholar
• Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother. 2008;8:515–517.
   PubMedGoogle Scholar
• Folkman J. Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594–607.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729.
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol. 2010;2010:689018.
   PubMedGoogle Scholar
• Roullin VG, Deverre JR, Lemaire L, et al. Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm. 2002;53:293–299.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006;11:152–164.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Kim TG, Park TG. Surface-functionalized electrospun nanofibers for tissue engineering and drug delivery. Adv Drug Deliv Rev. 2009;61:1033–1042.
   PubMed Web of Science ®Google Scholar
• Kim K, Luu YK, Chang C, et al. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release. 2004;98:47–56.
   PubMed Web of Science ®Google Scholar
• Zeng J, Yang L, Liang Q, et al. Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation. J Control Release. 2005;105:43–51.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674:171–174.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Influence of chronobiology on the nanoparticle-mediated drug uptake into the brain. Pharmaceutics. 2015;7:3–9.
   PubMed Web of Science ®Google Scholar
• Sipos EP, Tyler B, Piantadosi S, et al. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol. 1997;39:383–389.
   PubMed Web of Science ®Google Scholar
• Tyler B, Wadsworth S, Recinos V, et al. Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro Oncol. 2011;13:700–709.
   PubMed Web of Science ®Google Scholar
• Xu X, Chen X, Xu X, et al. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells. J Control Release. 2006;114:307–316.
   PubMed Web of Science ®Google Scholar
• Lee JS, An TK, Chae GS, et al. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm. 2005;59:169–175.
   PubMed Web of Science ®Google Scholar
• Seong H, An TK, Khang G, et al. BCNU-loaded poly(d, l-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm. 2003;251:1–12.
   PubMed Web of Science ®Google Scholar
• Menei P, Boisdron-Celle M, Croue A, et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery. 1996;39:117–123.
   PubMed Web of Science ®Google Scholar
• Weingart JD, Thompson RC, Tyler B, et al. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer. 1995;62:605–609.
   PubMed Web of Science ®Google Scholar
• Fournier E, Passirani C, Colin N, et al. Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers. Eur J Pharm Biopharm. 2004;57:189–197.
   PubMed Web of Science ®Google Scholar
• Yang HW, Hua MY, Liu HL, et al. Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials. 2011;32:6523–6532.
   PubMed Web of Science ®Google Scholar
• Hua MY, Liu HL, Yang HW, et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials. 2011;32:516–527.
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109:759–767.
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Khalansky AS, Gelperina S, et al. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One. 2011;6:e19121.
   PubMed Web of Science ®Google Scholar
• Xie H, Smith JW. Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system. J Nanobiotechnology. 2010;8:18.
   PubMedGoogle Scholar
• Decuzzi P, Pasqualini R, Arap W, et al. Intravascular delivery of particulate systems: does geometry really matter? Pharm Res. 2009;26:235–243.
   PubMed Web of Science ®Google Scholar
• Wiley DT, Webster P, Gale A, et al. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A. 2013;110:8662–8667.
   PubMed Web of Science ®Google Scholar
• Barbu E, Molnar E, Tsibouklis J, et al. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv. 2009;6:553–565.
   PubMed Web of Science ®Google Scholar
• Tseng YY, Liu SJ. Nanofibers used for the delivery of analgesics. Nanomedicine (Lond). 2015;10:1785–1800.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Liao IC, Adler A, et al. Electrohydrodynamics: a facile technique to fabricate drug delivery systems. Adv Drug Deliv Rev. 2009;61:1043–1054.
   PubMed Web of Science ®Google Scholar
• Song B, Wu C, Chang J. Dual drug release from electrospun poly(lactic-co-glycolic acid)/mesoporous silica nanoparticles composite mats with distinct release profiles. Acta Biomater. 2012;8:1901–1907.
   PubMed Web of Science ®Google Scholar
• Cui W, Li X, Zhu X, et al. Investigation of drug release and matrix degradation of electrospun poly(DL-lactide) fibers with paracetanol inoculation. Biomacromolecules. 2006;7:1623–1629.
   PubMed Web of Science ®Google Scholar
• Xie J, Macewan MR, Willerth SM, et al. Conductive core-sheath nanofibers and their potential application in neural tissue engineering. Adv Funct Mater. 2009;19:2312–2318.
   PubMed Web of Science ®Google Scholar
• Lee CH, Lin YH, Chang SH, et al. Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery. Int J Nanomed. 2014;9:311–326.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Keir S, Pegg AE, et al. O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther. 2002;1:943–948.
   PubMed Web of Science ®Google Scholar
• Koch D, Hundsberger T, Boor S, et al. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol. 2007;82:85–89.
   PubMed Web of Science ®Google Scholar
• Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–225.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–4740.
   PubMed Web of Science ®Google Scholar
• Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012;18:3428–3439.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano. 2014;8:5494–5514.
   PubMed Web of Science ®Google Scholar